Journal of Urban Health

, Volume 78, Issue 1, pp 152–161 | Cite as

Incidence of HIV among injection drug users entering drug treatment programs in four US cities

  • Christopher S. MurrillEmail author
  • D. Rebecca Prevots
  • Martha S. Miller
  • Laurie A. Linley
  • Janet E. Royalty
  • Marta Gwinn
Original Articles


We estimated seroincidence of human immunodeficiency virus (HIV) and prevalence of risk behaviors among injection drug users (IDUs) who accepted voluntary HIV testing on entry to drug treatment. Record-based incidence studies were conducted in 12 drug treatment programs in New York City (n = 890); Newark, New Jersey (n = 521); Seattle, Washington (n = 1,256); and Los Angeles, California (n = 733). Records of confidential HIV tests were abstracted for information on demographics, drug use, and HIV test results. More detailed data on risk behaviors were obtained by a standardized questionnaire. Although overall incidence rates were relatively low in this population (<1/100 person-years), there was a high prevalence of risk behaviors. Needle sharing was reported by more than one-third of the participants in each of the cities. HIV seroincidence rates were up to three-fold higher among younger ID Us. We found that HIV continued to be transmitted among ID Us who had received both drug treatment and HIV counseling and testing. HIV/AIDS (acquired immunodeficiency syndrome) prevention education should continue to be an important component of drug treatment.


HIV HIV Risk Behavior Incidence Injection Drug Use Prevalence 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Centers for Disease Control and Prevention. AIDS associated with injecting drug use—United States, 1995. MMWR Morb Mortal Wkly Rep. 1996;45:392–398.Google Scholar
  2. 2.
    Prevots DR, Allen DM, Lehman JS, Green TA, Petersen LR, Gwinn M. Trends in human immunodeficiency virus seroprevalence among injecting drug users entering drug treatment centers, United States, 1988-93. Am J Epidemiol. 1996;143:733–742.PubMedGoogle Scholar
  3. 3.
    Orr MF, Glebatis D, Friedman P, Des Jarlais DC, Prevots DR. Incidence of HIV infection in a New York City methadone maintenance treatment program. JAMA. 1996;276:99.CrossRefPubMedGoogle Scholar
  4. 4.
    Nelson KE, Vlahov D, Solomon L, Cohn S, Munoz A. Temporal trends in incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Maryland. Arch Intern Med. 1995;155:1305–1311.CrossRefPubMedGoogle Scholar
  5. 5.
    Des Jarlais DC, Marmot M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programs. Lancet. 1996;348:987–991.CrossRefPubMedGoogle Scholar
  6. 6.
    Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Oshmond D. HIV seroconvergsion in intraveneous drug users in San Francisco, 1985–1990. AIDS. 1994;8:223–231.CrossRefPubMedGoogle Scholar
  7. 7.
    Kerndt P, Weber M, Ford W, Prevots DR, Lehman JS Jr. HIV incidence among injecting drug users enrolled in a Los Angeles methadone program. JAMA. 1995;273:1831–1832.CrossRefPubMedGoogle Scholar
  8. 8.
    Jones TS, Allen DM, Onorato IM, Petersen LR, Dondero TJ, Pappaioanou M. HIV seroprevalence surveys in drug treatment centers. Public Health Rep. 1990;105:125–130.PubMedGoogle Scholar
  9. 9.
    Centers for Disease Control and Prevention. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep. 1989;38(S-7):1–7.Google Scholar
  10. 10.
    Substance Abuse and Mental Health Services Administration. Preliminary results from the 1996 National Household Survey on Drug Abuse Rockville, MD: Substance Abuse and Mental Health Services Administration; 1997:25.Google Scholar
  11. 11.
    Friedman SR, Jose B, Deren S, Des Jarlais DC, Neaigus A. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. Am J Epidemiol. 1996;142:864–874.Google Scholar
  12. 12.
    Battjes RJ, Pickens RW, Brown LS. HIV infection and AIDS risk behaviors among injecting drug users entering methadone treatment: an update. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:90–96.PubMedGoogle Scholar
  13. 13.
    Wiebel WW, Jimenez A, Johnson W, et al. Risk behaviors and HIV seroincidence among out-of-treatment injection drug users: a four-year prospective study. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:282–289.PubMedGoogle Scholar
  14. 14.
    Goldstein MF, Friedman SR, Neaigus A, Jose B, Ildefonso G, Curtis R. Self reports of HIV risk behaviors by injecting drug users: are they reliable? Addiction. 1995;90:1097–1104.CrossRefPubMedGoogle Scholar
  15. 15.
    Samuels JF, Vlahov D, Anthony JC, Chaisson RE. Measurement of HIV risk behaviors among intravenous drug users. Br J Addict. 1992;87:417–428.CrossRefPubMedGoogle Scholar
  16. 16.
    Hoffman JP, Su SS, Pach A. Changes in network characteristics and HIV risk behavior among injection drug users. Drug Alcohol Depend. 1997;46:41–51.CrossRefGoogle Scholar
  17. 17.
    Neaigus A, Friedman SR, Jose B, et al. High-risk personal networks and syringe sharing as a risk factors for HIV infection among new drug injectors. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:499–509.PubMedGoogle Scholar
  18. 18.
    McCusker J, Bigelow C, Zapka JG, Zorn M, Stoddard AM, Lewis BF. HIV-1 antibos participating in AIDS education. Patient Educ Couns. 1994;24:267–278.CrossRefPubMedGoogle Scholar
  19. 19.
    Valdiserri RO, Jones TS, West GR, Campbell CH Jr, Thompson PI. Where injecting drug users receive HIV counseling and testing. Public Health Rep. 1993;108:294–298.PubMedGoogle Scholar
  20. 20.
    Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver Injecting Drug Use Study. AIDS. 1997;11:F59-F65.CrossRefPubMedGoogle Scholar
  21. 21.
    Levine OS, Vlahov D, Brookmeyer R, Cohn S, Nelson KE. Differences in the incidence of hepatitis B and human immunodeficiency syndrome among injecting drug users. J Infec Dis. 1996;173:579–583.Google Scholar
  22. 22.
    Monterrosso E, Holmberg S, Robertson P. East versus West Coast differences in risks for and incidence of HIV among injection drug users (IDUs) in the Collaborative IDU Studies (CIDUS). In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22–26, 1997; Washington, DC. Abstract 377.Google Scholar
  23. 23.
    MacGowan RJ, Brackbill RM, Rugg DL, et al. Sex, drugs, and HIV counseling and testing: a prospective study of behavior-change among methadone-maintenance clients in New England. AIDS. 1997;11:229–235.CrossRefPubMedGoogle Scholar
  24. 24.
    Higgins DL, Galavotti C, O’Reilly KR, et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA. 1991;266:2419–2429.CrossRefPubMedGoogle Scholar
  25. 25.
    Wells EA, Calsyn DA, Clark LL, Saxon AJ, Jackson TR. Retention in methadone maintenance is associated with reduction in different HIV risk behaviors for women and men. Am J Drug Alcohol Abuse. 1996;22:509–521.CrossRefPubMedGoogle Scholar
  26. 26.
    Caplehorn JR, Ross MW. Methadone maintenance and the likelihood of risky needlesharing. Int J Addict. 1995;30;685–698.PubMedGoogle Scholar
  27. 27.
    Rhodes F, Malotte CK. HIV risk interventions for active drug users: experience and prospects. In: Oskamp S, eds. Understanding and Preventing HIV Risk Behaviors: Safer Sex and Drug Use. Thousand Oaks, CA: Sage Publications, Inc.; 1996:211–214.Google Scholar
  28. 28.
    Mahon N. New York inmates’ HIV risk behaviors: the implications for prevention policy and programs. Am J Public Health. 1996;86:1211–1215.CrossRefPubMedGoogle Scholar
  29. 29.
    Polonsky S, Kerr S, Harris B, Gaiter J, Fichtner RR, Kennedy MG. HIV prevention in prisons and jails: obstacles and opportunities. Public Health Rep. 1994;109:615–625.PubMedGoogle Scholar
  30. 30.
    Janssen RS, Satten GA, Strainer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42–48.CrossRefPubMedGoogle Scholar

Copyright information

© The New York Academy of Medicine 2001

Authors and Affiliations

  • Christopher S. Murrill
    • 1
    Email author
  • D. Rebecca Prevots
    • 1
  • Martha S. Miller
    • 1
  • Laurie A. Linley
    • 1
  • Janet E. Royalty
    • 1
  • Marta Gwinn
    • 1
  1. 1.Centers for Disease Control and PreventionAtlanta

Personalised recommendations